DYNE-301
Facioscapulohumeral Muscular Dystrophy (FSHD)
Key Facts
Indication
Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase
Phase 1/2
Status
Active
Company
About Dyne Therapeutics
Dyne Therapeutics is focused on developing life-transforming therapies for patients with genetically driven muscle diseases through its proprietary FORCE™ (Fragment, Oligonucleotide, Conjugate) platform. This platform enables the targeted delivery of therapeutic payloads to muscle tissue, addressing the root cause of diseases with high unmet need. The company has rapidly advanced multiple candidates into clinical development, with promising early data demonstrating target engagement and biomarker correction. Dyne's strategic approach combines validated oligonucleotide modalities with tissue-specific targeting to overcome historical delivery challenges in muscle disorders.
View full company profileTherapeutic Areas
Other Facioscapulohumeral Muscular Dystrophy (FSHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AOC Program | Avidity Biosciences | Clinical |
| Losmapimod (FHD-286) | Fulcrum Therapeutics | Phase 3 |
| DX5057 | Altay Therapeutics | Preclinical |